Abstract
Luspatercept (Reblozyl) was recently approved for treating patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) with ring sid......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
